ArticleTherapeutic advances in medical oncology2025

Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs.

Caifeng Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.